Literature DB >> 12051699

Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3.

Tatsuro Kanaki1, Hideaki Bujo, Seijiro Mori, Zhu Yanjuan, Kazuo Takahashi, Koutaro Yokote, Nobuhiro Morisaki, Yasushi Saito.   

Abstract

Platelet-derived growth factor (PDGF) stimulates expression of matrix metalloproteinases (MMPs), including stromelysin-1 (MMP-3). Induction of these expressions is known to occur during the course of atherosclerosis, tumor invasion, and metastasis. We investigated PDGF-alpha receptor (alphaR)- and beta receptor (betaR)-mediated signaling pathways for the expression of MMP-3 and invasion activity using porcine aortic endothelial (PAE) cells with stable expression of normal or mutated PDGF receptors. RT-PCR and Western blot analyses revealed that PDGF-BB induces MMP-3 expression in PAE cells that exclusively express either the PDGF-alphaR or the -betaR, but not in non-transfected control cells. To identify the signals necessary for PDGF receptor-mediated induction of MMP-3 expression, several lines of PAE cells expressing mutant PDGF receptors were further analyzed. Cells expressing mutant PDGF receptors unable to associate with Src or PLCgamma, retained the ability to induce MMP-3 expression as a result of PDGF-BB stimulation. However, incubation with PDGF-BB did not induce MMP-3 expression in cells expressing a mutant PDGF-betaR unable to associate with phosphatidylinositol 3(')-kinase (PI3K). LY294002, a PI3K inhibitor, reduced PDGF-BB-stimulated MMP-3 expression in PAE cells expressing wild-type PDGF receptors. In contrast, PDGF-BB induced MMP-3 expression in the presence of U-73122, a PLCgamma inhibitor. Moreover, PDGF-BB enhanced the invasiveness of cells expressing wild type PDGF-beta receptors, but not of cells expressing mutant PDGF-betaRs impaired in their ability to associate with PI3K. In light of these results, it appears that PDGF-BB is capable of inducing MMP-3 expression through both the PDGF-alphaR and the -betaR, and the effects are contributed by the PI3K-mediated transduction pathways. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051699     DOI: 10.1016/S0006-291X(02)00468-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects.

Authors:  S Miyazawa-Hoshimoto; K Takahashi; H Bujo; N Hashimoto; Y Saito
Journal:  Diabetologia       Date:  2003-10-08       Impact factor: 10.122

2.  Fibroblast activation protein α-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation.

Authors:  Zhang Wen; Qiaofei Liu; Jihua Wu; Banghao Xu; Jilong Wang; Lizhou Liang; Ya Guo; Minhao Peng; Yupei Zhao; Quan Liao
Journal:  Ann Transl Med       Date:  2019-10

Review 3.  The genetic basis for altered blood vessel function in disease: large artery stiffening.

Authors:  Alex Agrotis
Journal:  Vasc Health Risk Manag       Date:  2005

4.  Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells.

Authors:  Feng Tian; Ding Ding; Dandan Li
Journal:  Int J Oncol       Date:  2015-04-09       Impact factor: 5.650

Review 5.  [The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance].

Authors:  Bingjing Zhu; Xiangdong Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-08

Review 6.  Targeting PI3K/Akt signal transduction for cancer therapy.

Authors:  Yan He; Miao Miao Sun; Guo Geng Zhang; Jing Yang; Kui Sheng Chen; Wen Wen Xu; Bin Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-16

7.  Disruption of phosphoinositide-specific phospholipases Cγ1 contributes to extracellular matrix synthesis of human osteoarthritis chondrocytes.

Authors:  Guoqing Zeng; Xu Cui; Zejun Liu; Honghai Zhao; Xinpeng Zheng; Bing Zhang; Chun Xia
Journal:  Int J Mol Sci       Date:  2014-07-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.